Dudediligence.

Evommune, Inc

EVMNNYSE · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$0.00Dec ’24$3.0MMar ’25$10.0MSep ’25$0.00Dec ’25$0.00Mar ’26$0.00Jun ’26
Net income, by quarter
−$15.9MSep ’24−$20.7MDec ’24−$14.6MMar ’25−$12.5MSep ’25−$28.3MDec ’25−$21.7MMar ’26−$32.2MJun ’26
Fiscal years, by the month each ended
LineDec 2023Dec 2024Dec 2025
Revenuenone on file$7.0M$13.0M
Operating incomenone on file−$70.0M−$81.1M
Net incomenone on file−$66.8M−$68.9M
Operating cash flownone on file−$58.2M−$76.4M
Free cash flownone on file−$58.3M−$76.7M
Cash$29.2M$16.3M$44.1M
Shares outstandingnone on file1.6M31.5M